CLN3 and retinitis pigmentosa 1: Genome-editing approaches using CRISPR/Cas9 have rescued the disease phenotype in iPSCs from patients with RP, XLRS, LCA4, LCA5, enhanced S-cone syndrome, or nonsyndromic retinopathy harboring CLN3 mutations, by revealing differentiation into ROs [34, 38–40, 48, 54, 66, 76, 87, 128, 129].